Source:http://linkedlifedata.com/resource/pubmed/id/15956686
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:dateCreated |
2005-6-15
|
pubmed:abstractText |
A novel member of the human relaxin subclass of the insulin superfamily was recently discovered during a genomics database search and named relaxin-3. Like human relaxin-1 and relaxin-2, relaxin-3 is predicted to consist of a two-chain structure and three disulfide bonds in a disposition identical to that of insulin. To undertake detailed biophysical and biological characterization of the peptide, its chemical synthesis was undertaken. In contrast to human relaxin-1 and relaxin-2, however, relaxin-3 could not be successfully prepared by simple combination of the individual chains, thus necessitating recourse to the use of a regioselective disulfide bond formation strategy. Solid phase synthesis of the separate, selectively S-protected A and B chains followed by their purification and the subsequent stepwise formation of each of the three disulfides led to the successful acquisition of human relaxin-3. Comprehensive chemical characterization confirmed both the correct chain orientation and the integrity of the synthetic product. Relaxin-3 was found to bind to and activate native relaxin receptors in vitro and stimulate water drinking through central relaxin receptors in vivo. Recent studies have demonstrated that relaxin-3 will bind to and activate human LGR7, but not LGR8, in vitro. Secondary structural analysis showed it to adopt a less ordered confirmation than either relaxin-1 or relaxin-2, reflecting the presence in the former of a greater percentage of nonhelical forming amino acids. NMR spectroscopy and simulated annealing calculations were used to determine the three-dimensional structure of relaxin-3 and to identify key structural differences between the human relaxins.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0077-8923
|
pubmed:author |
pubmed-author:BathgateRoss ARA,
pubmed-author:CraikDavid JDJ,
pubmed-author:DedeKK,
pubmed-author:FerraroTaniaT,
pubmed-author:GundlachAndrewA,
pubmed-author:HansonNicola FNF,
pubmed-author:LayfieldSharonS,
pubmed-author:MaSherieS,
pubmed-author:RosengrenJohanJ,
pubmed-author:SummersRoger JRJ,
pubmed-author:TregearGeoffrey WGW,
pubmed-author:WadeJohn DJD
|
pubmed:issnType |
Print
|
pubmed:volume |
1041
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
40-6
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading | |
pubmed:year |
2005
|
pubmed:articleTitle |
The chemistry and biology of human relaxin-3.
|
pubmed:affiliation |
Howard Florey Institute of Experimental Physiology and Medicine, Parkville, Victoria, 3010, Australia. g.tregear@hfi.unimelb.edu.au
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|